Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.87
LZAGY's Cash to Debt is ranked higher than
56% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. LZAGY: 0.87 )
LZAGY' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.87

Equity to Asset 0.33
LZAGY's Equity to Asset is ranked higher than
53% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. LZAGY: 0.33 )
LZAGY' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.5
Current: 0.33

0.3
0.5
F-Score: 4
Z-Score: 1.77
M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 3.74
LZAGY's Operating margin (%) is ranked higher than
83% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. LZAGY: 3.74 )
LZAGY' s 10-Year Operating margin (%) Range
Min: 3.74   Max: 15.02
Current: 3.74

3.74
15.02
Net-margin (%) 2.43
LZAGY's Net-margin (%) is ranked higher than
82% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. LZAGY: 2.43 )
LZAGY' s 10-Year Net-margin (%) Range
Min: 2.43   Max: 14.27
Current: 2.43

2.43
14.27
ROE (%) 4.09
LZAGY's ROE (%) is ranked higher than
85% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. LZAGY: 4.09 )
LZAGY' s 10-Year ROE (%) Range
Min: 4.09   Max: 21.66
Current: 4.09

4.09
21.66
ROA (%) 1.33
LZAGY's ROA (%) is ranked higher than
83% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. LZAGY: 1.33 )
LZAGY' s 10-Year ROA (%) Range
Min: 1.33   Max: 7.45
Current: 1.33

1.33
7.45
ROC (Joel Greenblatt) (%) 4.71
LZAGY's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. LZAGY: 4.71 )
LZAGY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.71   Max: 27.77
Current: 4.71

4.71
27.77
Revenue Growth (%) 10.50
LZAGY's Revenue Growth (%) is ranked higher than
84% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. LZAGY: 10.50 )
LZAGY' s 10-Year Revenue Growth (%) Range
Min: -5.5   Max: 12.8
Current: 10.5

-5.5
12.8
EBITDA Growth (%) -11.80
LZAGY's EBITDA Growth (%) is ranked higher than
72% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. LZAGY: -11.80 )
LZAGY' s 10-Year EBITDA Growth (%) Range
Min: -12.4   Max: 48.1
Current: -11.8

-12.4
48.1
EPS Growth (%) -32.90
LZAGY's EPS Growth (%) is ranked higher than
62% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. LZAGY: -32.90 )
LZAGY' s 10-Year EPS Growth (%) Range
Min: -32.9   Max: 29.6
Current: -32.9

-32.9
29.6
» LZAGY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with LZAGY



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 57.30
LZAGY's P/E(ttm) is ranked higher than
87% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. LZAGY: 57.30 )
LZAGY' s 10-Year P/E(ttm) Range
Min: 8.61   Max: 59.55
Current: 57.3

8.61
59.55
P/B 2.30
LZAGY's P/B is ranked higher than
88% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. LZAGY: 2.30 )
LZAGY' s 10-Year P/B Range
Min: 0.74   Max: 3.83
Current: 2.3

0.74
3.83
P/S 1.40
LZAGY's P/S is ranked higher than
96% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. LZAGY: 1.40 )
LZAGY' s 10-Year P/S Range
Min: 0.63   Max: 2.58
Current: 1.4

0.63
2.58
PFCF 16.10
LZAGY's PFCF is ranked higher than
97% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. LZAGY: 16.10 )
LZAGY' s 10-Year PFCF Range
Min: 6.28   Max: 210.54
Current: 16.1

6.28
210.54
EV-to-EBIT 38.03
LZAGY's EV-to-EBIT is ranked higher than
89% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. LZAGY: 38.03 )
LZAGY' s 10-Year EV-to-EBIT Range
Min: 9.9   Max: 40.8
Current: 38.03

9.9
40.8
Shiller P/E 21.80
LZAGY's Shiller P/E is ranked higher than
98% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. LZAGY: 21.80 )
LZAGY' s 10-Year Shiller P/E Range
Min: 6.25   Max: 22.6
Current: 21.8

6.25
22.6
Current Ratio 1.57
LZAGY's Current Ratio is ranked higher than
56% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. LZAGY: 1.57 )
LZAGY' s 10-Year Current Ratio Range
Min: 0.97   Max: 1.84
Current: 1.57

0.97
1.84
Quick Ratio 0.92
LZAGY's Quick Ratio is ranked higher than
53% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. LZAGY: 0.92 )
LZAGY' s 10-Year Quick Ratio Range
Min: 0.62   Max: 1.09
Current: 0.92

0.62
1.09

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.10
LZAGY's Dividend Yield is ranked higher than
87% of the 166 Companies
in the Global Biotechnology industry.

( Industry Median: 1.16 vs. LZAGY: 2.10 )
LZAGY' s 10-Year Dividend Yield Range
Min: 1.61   Max: 4.15
Current: 2.1

1.61
4.15
Dividend Payout 1.17
LZAGY's Dividend Payout is ranked higher than
81% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. LZAGY: 1.17 )
LZAGY' s 10-Year Dividend Payout Range
Min: 0.42   Max: 0.47
Current: 1.17

0.42
0.47
Yield on cost (5-Year) 2.10
LZAGY's Yield on cost (5-Year) is ranked higher than
76% of the 170 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. LZAGY: 2.10 )
LZAGY' s 10-Year Yield on cost (5-Year) Range
Min: 1.61   Max: 4.15
Current: 2.1

1.61
4.15
Share Buyback Rate 0.30
LZAGY's Share Buyback Rate is ranked higher than
96% of the 724 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. LZAGY: 0.30 )
LZAGY' s 10-Year Share Buyback Rate Range
Min: 0.6   Max: -3.4
Current: 0.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 17.60
LZAGY's Price/Tangible Book is ranked higher than
64% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. LZAGY: 17.60 )
LZAGY' s 10-Year Price/Tangible Book Range
Min: 2.27   Max: 15.87
Current: 17.6

2.27
15.87
Price/DCF (Projected) 2.10
LZAGY's Price/DCF (Projected) is ranked higher than
95% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. LZAGY: 2.10 )
LZAGY' s 10-Year Price/DCF (Projected) Range
Min: 1.12   Max: 2.12
Current: 2.1

1.12
2.12
Price/Median PS Value 1.00
LZAGY's Price/Median PS Value is ranked higher than
86% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. LZAGY: 1.00 )
LZAGY' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 1.6
Current: 1

0.46
1.6
Price/Graham Number 6.60
LZAGY's Price/Graham Number is ranked higher than
87% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. LZAGY: 6.60 )
LZAGY' s 10-Year Price/Graham Number Range
Min: 1.17   Max: 5.97
Current: 6.6

1.17
5.97
Earnings Yield (Greenblatt) 2.60
LZAGY's Earnings Yield (Greenblatt) is ranked higher than
57% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. LZAGY: 2.60 )
LZAGY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.5   Max: 10.1
Current: 2.6

2.5
10.1
Forward Rate of Return (Yacktman) -3.16
LZAGY's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. LZAGY: -3.16 )
LZAGY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.3   Max: 43.8
Current: -3.16

-13.3
43.8

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:O6Z.Singapore, LONN.Switzerland, LO3.Germany
Lonza Group AG was founded in 1897 and is headquartered in Basel, Switzerland. The Company supplies products and services to the pharmaceutical and biotechnology, healthcare, and life-science industries worldwide. The Company operates in four segments which are Custom Manufacturing, Life science ingredient, Microbial control segment, Bioscience segment. Its Custom Manufacturing segment manufactures active ingredients that are used in critical drugs for treating patients with cardiovascular diseases, cancer, neurological, and infectious diseases. The Company's Life Science Ingredients segment offers products used in nutrition, microbial control, and selected industrial markets. The Company's Microbial Control segment provides chemistry-based and related solutions to destroy or selectively inhibit the growth of harmful microorganisms in the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. The Company's Bioscience segment develops tools that help life science customers to discover, develop, and test therapeutics. The Company also serves pharmaceutical and biotechnology companies, and academic and government research organizations.
» More Articles for OTCPK:LZAGY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Lonzagard® RCS™ Family of Spray Disinfectant Combats Norovirus on Land and Sea Jul 17 2014
Lonza Completes Successful Implementation of Next-Generation Carniking Process Mar 27 2014
Lonza Publishes Annual Report 2013 and Invitation to the Annual General Meeting 2014 Mar 20 2014
Lonza and BioWa Sign POTELLIGENT® CHOK1SV Cell Line Technology Licensing Agreement with arGEN-X Mar 19 2014
Board of Directors Proposes Barbara Richmond and Juergen Steinemann as New Board Members – Peter... Mar 04 2014
Lonza Offers Lonzagard® Disinfectants for Flu Virus Infection Prevention and Control Feb 25 2014
Lonza Signs Exclusive Agreement with Index Ventures for the Development and Manufacture of Biologics... Jan 28 2014
Lonza Extends Partnership with Pharmacyclics to Support Manufacturing of Recently Approved Oncology... Jan 28 2014
Mercury Pollution in the Upper Valais Collaboration Announced Between the Canton of Valais and Lonza Jan 28 2014
Lonza Delivers Strong Results Following Continuing Success of Transformation Efforts Jan 28 2014
After A Big Rally, What Propels Lonza Now? Dec 12 2013
New Study Identifies the Ability of ResistAid™ to Enhance Immune Response at Lower Dosage Nov 13 2013
Lonza Announces the Availability of Its XS Microbial Expression Technology™ Portfolio to Customers... Nov 05 2013
Lonza Business Performance Remains on Track Oct 31 2013
Lonza Progresses Well with Transformational Activities and Delivers Better Than Expected Half Year... Jul 25 2013
Teva and Lonza Announce Mutual Decision to Discontinue Biologics Joint Venture Jul 25 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide